The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistanc...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Wiesmann, Frank, Vachta, Jan, Ehret, Robert, Walter, Hauke, Kaiser, Rolf, Stürmer, Martin, Tappe, André, Däumer, Martin, Berg, Thomas, Naeth, Gudrun, Braun, Patrick, Knechten, Heribert
Format:	Artigo
Sprog:	Inglês
Udgivet:	BioMed Central 2011
Fag:	Short Report
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3049128/ https://ncbi.nlm.nih.gov/pubmed/21314993 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-6405-8-7
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

Lignende værker